What Is Driving Recursion (RXRX) Stock Up Today?

As of the most recent check, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock was up 10.98% to trade at $13.99, continuing its upward trend. Recursion’s stock has increased in response to a major disclosure about a new database project. Recursion (RXRX) showcased LOWE (Large Language Model-Orchestrated Workflow Engine) in action.

LOWE is a new program developed by RXRX that uses a natural language interface to carry out intricate drug discovery activities. It can coordinate studies utilizing Recursion’s automated wet laboratories and is driven by Recursion’s exclusive biological and chemical data, releasing the full potential of the Recursion Operating System in a user-friendly application.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Over the last ten years, Recursion has worked to compile one of the largest biological and chemical databases in the world. In addition, the company has developed automated wet-lab and dry-lab technologies that enable scientists to swiftly decipher biology and identify and progress promising initiatives.

Large Language Models have learned to utilize many of Recursion’s tools and data for the first time, far more easily and scalable than an experienced scientist would. LOWE is a step toward the creation of autonomous “AI scientists” for therapeutic research and offers an intriguing peek at what RXRX believes the future of drug discovery will hold.

During Recursion’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Co-founder and CEO of Recursion Chris Gibson revealed LOWE. Recursion and NVIDIA will co-host an invite-only event on Wednesday, January 10, with further LOWE software demonstrations and an amazing roster of speakers.

LOWE was created by Recursion’s AI research engine, Valence Labs, after Valence Discovery was acquired by Recursion in May 2023. The creation of Foundation models that faithfully depict or recreate the biological and chemical realms of drug discovery is just one of the many projects Valence is leading to improve the future of AI-enabled scientific discovery.

While reasoning and orchestration systems like LOWE can plan and carry out experiments for hypothesis testing, inference engines and active learners are used to develop hypotheses and learn from the findings.

Most Popular

Related posts